BCMA/TNFRSF17, Cynomolgus (HEK293, Fc) | Gentaur

Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Dry Ice Shipment: No

Alternative Products

Cat	Name
UA010659-P-01	BCMA/TNFRSF17 Fc Chimera Protein, Cynomolgus
UA010659-P-03	BCMA/TNFRSF17 Fc Chimera Protein, Cynomolgus
UA011094-P-03	BCMA/TNFRSF17 His Tag Protein, Cynomolgus
RP02009	Recombinant Cynomolgus TNFRSF17/BCMA/CD269 Protein
PKSQ050104-01	Recombinant Cynomolgus BCMA/TNFRSF17 (C-6His)
MBS2569400-03	Recombinant Cynomolgus BCMA/TNFRSF17 (C-6His)
UA011094-P-01	BCMA/TNFRSF17 His Tag Protein, Cynomolgus
PKSQ050104-02	Recombinant Cynomolgus BCMA/TNFRSF17 (C-6His)
UA010659-P-02	BCMA/TNFRSF17 Fc Chimera Protein, Cynomolgus
UA011094-P-02	BCMA/TNFRSF17 His Tag Protein, Cynomolgus

BCMA/TNFRSF17, Cynomolgus (HEK293, Fc)

CAT:

804-HY-P7839

Size:

Inquire

Price:

Ask

For price, please contact [email protected].

BCMA/TNFRSF17, Cynomolgus (HEK293, Fc)

UNSPSC Description: B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells[1]. BCMA/TNFRSF17 Protein, Cynomolgus (HEK293, Fc) is a recombinant protein with a C-Terminal Fc label, It consists of 53 amino acids (M1-A53) and is produced in HEK293 cells.
Type: Recombinant Proteins
Assay Protocol: https://www.medchemexpress.com/cytokines/bcma-tnfrsf17-protein-cynomolgus-hek-293-fc.html
Smiles: MLQMARQCSQ NEYFDSLLHD CKPCQLRCSS TPPLTCQRYC NASMTNSVKG MNA
Molecular Weight: 38-45 kDa
References & Citations: [1]Nobari ST, et al. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. J Transl Med. 2022 Feb 10;20(1):82.|[2]Yu B, et al. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020 Sep 17;13(1):125.|[3]Perez-Amill L, et al. Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica. 2021 Jan 1;106(1):173-184.|[4]Sanchez E, et al. Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma. Clin Cancer Res. 2016 Jul 1;22(13):3383-97.|[5]O'Connor BP, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004 Jan 5;199(1):91-8.|[6]Tai YT, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 Jun 23;127(25):3225-36.
Shipping Conditions: Room temperature

Complementary Product Range

Our range of products, including BCMA/TNFRSF17, Cynomolgus (HEK293, Fc), falls within the same field of application and can be used across various research projects. These products are carefully selected for their high performance and reliability, supporting the diverse needs of modern laboratories. Whether for ongoing studies or future experiments, they are designed to help researchers achieve their scientific goals. Here are some related products that may be of interest for similar or future applications:

Related Products

Cat	Name
HY-P7839	BCMA/TNFRSF17, Cynomolgus (HEK293, Fc)
HY-P70778	BCMA/TNFRSF17, Cynomolgus (HEK293, His)
HY-P70827-01	BCMA/TNFRSF17, Human (HEK293, mFc)
HY-P7656-01	BCMA/TNFRSF17, Mouse (HEK293, Fc)
HY-P72847	BCMA/TNFRSF17, Human (HEK293, His)
HY-P75591-03	BCMA/TNFRSF17, Rat (HEK293, Fc)
HY-P7654-01	BCMA/TNFRSF17, Human (HEK293, Fc)
HY-P7656-02	BCMA/TNFRSF17, Mouse (HEK293, Fc)
HY-P70827-02	BCMA/TNFRSF17, Human (HEK293, mFc)
HY-P75591-01	BCMA/TNFRSF17, Rat (HEK293, Fc)

Each item in our collection, is tested for precision and quality, ensuring dependable solutions for your research. As we continue to incorporate the latest advancements, Gentaur ensures that our product range remains relevant and versatile, providing you with the tools needed for both current and future projects.

Find us on